DYSREGULATED LEUKOTRIENE METABOLISM IN COVID-19 PATIENTS

Halef Okan Doğan; Mahir Budak; Kübra Doğan; Gözde Ertürk Zararsız; Serra İlayda Yerlitaş; Serkan Bolat; Onur Şenol; Seyit Ali Büyüktuna; Ergun Pınarbaşı; Rağıp Sarıismailoğlu; Hayrettin Yavuz

doi:10.7883/yoken.JJID.2023.211

Halef Okan Doğan, Mahir Budak, Kübra Doğan, Gözde Ertürk Zararsız, Serra İlayda Yerlitaş, Serkan Bolat, Onur Şenol, Seyit Ali Büyüktuna, Ergun Pınarbaşı, Rağıp Sarıismailoğlu, Hayrettin Yavuz

Author information

Halef Okan Doğan
Department of Biochemistry, School of Medicine, Sivas Cumhuriyet University, Turkey
Mahir Budak
Department of Molecular Biology and Genetics, Faculty of Science, Sivas Cumhuriyet University, Turkey
Kübra Doğan
Department of Biochemistry, Sivas Numune Hospital, Turkey
Gözde Ertürk Zararsız
Department of Biostatistics, School of Medicine, Erciyes University, Turkey
Drug Application and Research Center (ERFARMA), Erciyes University, Turkey
Serra İlayda Yerlitaş
Department of Biostatistics, School of Medicine, Erciyes University, Turkey
Drug Application and Research Center (ERFARMA), Erciyes University, Turkey
Serkan Bolat
Department of Biochemistry, School of Medicine, Sivas Cumhuriyet University, Turkey
Onur Şenol
Department of Analytical Chemistry, Faculty of Pharmacy, Atatürk University, Turkey.
Seyit Ali Büyüktuna
Department of Infectious Diseases and Clinic Microbiology, School of Medicine, Sivas Cumhuriyet University, Turkey
Ergun Pınarbaşı
Department of Medical Biology, School of Medicine, Sivas Cumhuriyet University, Turkey
Rağıp Sarıismailoğlu
Department of Infectious Disease, Sivas State Hospital, Turkey
Hayrettin Yavuz
Division of Pediatric Nephrology, Department of Pediatrics, University of Virginia, USA

Keywords: COVID-19, cysteinyl leukotriene, 5-lipooxygenase, cysteinyl leukotriene receptor, 5-LO activating protein

JOURNAL FREE ACCESS Advance online publication

Article ID: JJID.2023.211

DOI https://doi.org/10.7883/yoken.JJID.2023.211

Details

Abstract

The aim of this study was to examine leukotriene metabolism in COVID-19. A total of 180 people were included in the study. Of these, 60 were healthy controls, 60 were patients who needed intensive care unit (ICU), and 60 were patients who did not need intensive care (non-ICU). Serum levels of 5-lipoxygenase (5-LO), 5-LO activating protein (ALOX5AP) and cysteinyl leukotriene (CYSLT) were measured and mRNA expressions of 5-LO, ALOX5AP and cysteinyl leukotriene receptor 1 (CYSLTR1) were investigated. As compared to the control group, both non-ICU and ICU groups had lower levels of 5-LO and mRNA expression. ICU patients had lower levels of 5-LO and mRNA expression compared with non-ICU patients. The expression of CYSLTR1 mRNA was higher in patients compared to healthy controls. CYSLTR1 mRNA expression was found to be higher in ICU group than in non-ICU group. CYSLT levels were higher in the control group compared to both non-ICU and ICU patients. Due to the higher expressions of CYSLTR1 in patients than control group, selective leukotriene receptor blockers can be used as a treatment option. CYSLTR1 expressions were also higher in ICU group than non-ICU group. Thus, CYSLTR1 mRNA expression could be a promising biomarker of COVID-19 severity.

Corresponding author

Register with J-STAGE for free!